| |
Course Chairs: Ray Monnat (UW) & Patrick Duffy (SBRI) |
|
| |
|
|
Session 1
May 2, 2007 |
Prof. Brian Greenwood
"The Global Burden of Malaria - Where do we start? What do we do?"
(PowerPoint slides - Part I)
(PowerPoint slides - Part II) |
|
| |
The global distribution of clinical episodes of Plasmodium
falciparum malaria (supp. info) |
|
| |
The economic and social burden of malaria |
|
| |
Malaria |
|
| |
|
|
Session 2
May 9, 2007 |
Prof. Janet Hemingway
"Malaria: Vector borne disease dynamics and vector control"
|
|
| |
(PowerPoint slides) |
|
| |
The Anopheles gambiae detoxification chip: A highly specific
microarray to study metabolic-based insecticide resistance
in malaria vectors |
|
| |
The Innovative Vector Control Consortium: improved control
of mosquito-borne diseases |
|
| |
Health risks and benefits of bis(4-chlorophenyl)-1,1,1-trichloroethane (DDT) |
|
| |
The Ecology of Genetically Modified Mosquitoes |
|
| |
Malaria Control with Genetically Manipulated Insect Vectors |
|
| |
|
|
Session 3
May 16, 2007 |
Dr. Thomas E. Wellems
"Treating malaria: What works, what doesn't and what's new" |
|
| |
(PowerPoint slides) |
|
| |
Malaria Websites |
|
| |
Antimalarial Drug Therapy: The Role of Parasite Biology and Drug Resistance |
|
| |
Chloroquine-Resistant Malaria |
|
| |
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial |
|
| |
|
|
Session 4
May 23, 2007 |
Dr. Patrick Duffy
"Pathogenesis of malaria: Who gets sick, who dies and why?" |
|
| |
Adherence of Plasmodium falciparum to Chondroitin Sulfate A in the Human Placenta |
|
| |
The pathogenic basis of malaria |
|
| |
Hypertension and Maternal-Fetal Conflict during Placental Malaria |
|
| |
Negative epistasis between the malaria-protective effects of α+-thalassemia and the sickle cell trait |
|
| |
|
|
Session 5
May 30, 2007
|
Dr. Stefan Kappe
"Malaria vaccines: New strategies for malaria prevention" |
|
| |
Development of vaccines against Plasmodium falciparum malaria: taking lessons from naturally acquired protective immunity |
|
| |
Genetically modified Plasmodium parasites as a protective experimental malaria vaccine |
|
| |
High road, low road? Choices and challenges on the pathway to a malaria vaccine |
|
| |
Immune responses to Plasmodium vivax pre-erythrocytic stage antigens in naturally exposed Duffy-negative humans: a potential model for identification of liver-stage antigens |
|
| |
|
|
Any use of lecture materials posted requires permission of author and credit to author. |
